Change 5-day change 1-year change 3-year change Capi.($)
-.--%+1.69% - - 0
+0.90%+3.80%+41.49%-0.81% 83.28B
+8.86%+129.20%+435.14%+25.70% 57.94B
+0.48%+25.64%-21.85%-35.91% 57.77B
-1.46%+0.19%-2.06%+32.21% 51.75B
-0.23%+2.69%+10.05%+171.48% 49.35B
+1.13%+3.31%+55.61%-18.13% 32.03B
+0.46%+6.37%+50.29%+97.70% 25.91B
-2.83%+4.35%-0.45%+187.16% 22.74B
-1.17%-0.52%+56.93%+109.48% 16.87B
Average -0.41%+20.47%+69.46%+63.21% 44.18B
Weighted average by Cap. -0.25%+24.98%+80.04%+44.08%
Logo Cangene Corporation
Emergent BioSolutions Canada Inc is a Canada-based biopharmaceutical company in the business of developing, manufacturing, and commercializing products and technologies for global markets. It operates in two segments: biopharmaceutical operations and contract services. The biopharmaceutical operations segment consist of sales of approved products and non- specialty plasma. The contract-services segment consists of third-party contract-manufacturing revenues at the Company's Winnipeg facilities, as well as at Cangene bioPharma in Baltimore. It also provides commercial contract-manufacturing services, primarily through a United States-based subsidiary. The Company's products include Rho(D) Immune Globulin (Human) for Injection (WinRho) SDF, Hepatitis B Immune Globulin (Human) Injection (HepaGam B) and Varicella Zoster Immune Globulin (Human) (VariZIG).
Employees
-